GRI BIO INC (GRI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.55+8.39%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · GRI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
GRI — officer appointment
Dated 2026-11-04
Director — W. Marc Hertz, Ph.D.; David Szekeres: The filing reports the routine election of two directors to the Board of Directors at the annual meeting.
Why it matters: The stated cash runway covers planned work only into Q2 2027. The company says a Phase 2b trial needs more funds.
Worry ifThe Nov. 13 update cuts the cash runway to before Q2 2027 or discloses a new financing need.
Less concerning ifThe company keeps its Q2 2027 runway estimate and reports no new funding need for planned work.
Why it matters: This step could add a second program beyond GRI-0621. A delay would leave the pipeline more reliant on one drug.
Supportive ifThe company reports that GRI-0803 has entered IND-enabling work by H1 2027.
Worry ifThe company says GRI-0803 has not entered IND-enabling work by the end of H1 2027, or delays the program.
Why it matters: The company has no approved product revenue in the inputs and relies on cash to fund research. Higher losses could shorten its runway.
Worry ifThe Nov. 13 report shows a quarterly net loss above $2.0 million or a cash balance below $11.0 million.
Less concerning ifThe report shows a net loss at or below $2.0 million and cash at or above $11.0 million.
Why it matters: The Phase 2a trial had 35 patients and lasted 12 weeks. Larger or longer tests can show if these early signals persist.
Supportive ifA new GRI-0621 study reports higher FVC than control. It finds no rise in serious safety events or treatment-related diarrhea.
Worry ifA new study finds no FVC benefit versus control. It also finds more serious safety events or treatment-related diarrhea.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$339 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $1,300 loss on $10,000 · 13.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,770 loss on $10,000 · 97.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The next study is the key test of the Phase 2a results. A clear start plan would show progress toward a larger trial.
Supportive ifManagement names a start window and key design details for the adaptive Phase 2b/3 study.
Worry ifManagement delays the study or says it lacks funds to begin it.